<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04374799</url>
  </required_header>
  <id_info>
    <org_study_id>2102</org_study_id>
    <nct_id>NCT04374799</nct_id>
  </id_info>
  <brief_title>Heparin vs Placebo for Cardiac Catheterization</brief_title>
  <official_title>A Randomized Trial of Heparin vs Placebo in Patients Undergoing Cardiac Catheterization Via the Trans-radial Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant,
      low dose anticoagulant and high dose anticoagulant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing diagnostic cardiac catheterization via the trans-radial approach will be
      randomly allocated (1:1:1) to receive either low-dose UFH (25 IU/Kg -maximal dose 3,000 IU),
      high-dose UFH 50 IU/kg -maximal dose 5,000 IU) or N/S 0.9%. After 30 minutes, patients will
      undergo a gradual wrist band release. Hematoma and radial artery occlusion will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hematoma</measure>
    <time_frame>1 hour</time_frame>
    <description>&gt;5 cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>radial artery occlusion</measure>
    <time_frame>1 hour</time_frame>
    <description>by ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>access site bleeding</measure>
    <time_frame>1 hour</time_frame>
    <description>any bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non access site bleeding</measure>
    <time_frame>1 day</time_frame>
    <description>bleeding not related to access site, such as gastrointestinal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>access site complications</measure>
    <time_frame>1 day</time_frame>
    <description>pseudoaneurysm, arteriovenous fistula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wrist band duration</measure>
    <time_frame>3 hours</time_frame>
    <description>How long wrist band was on</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to discharge</measure>
    <time_frame>1 day</time_frame>
    <description>when patient was able to leave the post procedure care area</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>Cardiac Disease</condition>
  <arm_group>
    <arm_group_label>Low dose heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>heparin (25 IU/Kg -maximal dose 3,000 IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>heparin 50 IU/kg -maximal dose 5,000 IU</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline 0.9%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>two doses of heparin</description>
    <arm_group_label>High dose heparin</arm_group_label>
    <arm_group_label>Low dose heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnostic cardiac catheterization 5 French sheath patency of the ulno-palmar
             circulation

        Exclusion Criteria:

        abnormal ulno-palmar circulation. Prior radial artery thrombosis Prior surgery close to the
        access site Emergent cardiac catheterization. History of HIT or allergy to heparin.
        Patients requiring anticoagulation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shahar Lavi, MD</last_name>
    <phone>519-6633611</phone>
    <email>Shahar.lavi@lhsc.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Shamir Mehta</last_name>
    </contact>
    <investigator>
      <last_name>Shamir Mehta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

